Empagliflozin and the risk of heart failure hospitalization in routine clinical care: a first analysis from the EMPRISE study
Background: The EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event
Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium-glucose …
Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium-glucose …
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
E Patorno, A Pawar, JM Franklin, M Najafzadeh… - Circulation, 2019 - europepmc.org
Background The EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event
Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium-glucose …
Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium-glucose …
[HTML][HTML] Empagliflozin and the risk of heart failure hospitalization in routine clinical care: a first analysis from the EMPagliflozin compaRative effectIveness and SafEty …
E Patorno, A Pawar, JM Franklin, M Najafzadeh… - Circulation, 2019 - ncbi.nlm.nih.gov
Background: The EMPA-REG OUTCOME trial showed that empagliflozin, a sodium-glucose
co-transporter-2 inhibitor (SGLT2i), reduces the risk of hospitalization for heart failure (HHF) …
co-transporter-2 inhibitor (SGLT2i), reduces the risk of hospitalization for heart failure (HHF) …
[PDF][PDF] Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care
E Patorno, A Pawar, JM Franklin, M Najafzadeh… - Circulation, 2019 - researchgate.net
BACKGROUND: The EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome
Event Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium …
Event Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium …
[PDF][PDF] Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care
E Patorno, A Pawar, JM Franklin, M Najafzadeh… - Circulation, 2019 - academia.edu
BACKGROUND: The EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome
Event Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium …
Event Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium …
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care
E Patorno, A Pawar, JM Franklin, M Najafzadeh… - Circulation, 2019 - Am Heart Assoc
BACKGROUND: The EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome
Event Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium …
Event Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium …
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care
E Patorno, A Pawar, JM Franklin, M Najafzadeh… - Circulation, 2019 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background:</jats: title>< jats: p> The EMPA-REG OUTCOME
trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients) …
trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients) …
[PDF][PDF] Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care
E Patorno, A Pawar, JM Franklin, M Najafzadeh… - …, 2019 - boehringerone.com
BACKGROUND: The EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome
Event Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium …
Event Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium …
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care
E Patorno, A Pawar, JM Franklin… - …, 2019 - pubmed.ncbi.nlm.nih.gov
Background The EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event
Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium-glucose …
Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium-glucose …
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
E Patorno, A Pawar, JM Franklin, M Najafzadeh… - Circulation, 2019 - europepmc.org
Background The EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event
Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium-glucose …
Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium-glucose …